<?xml version='1.0' encoding='utf-8'?>
<document id="2573205"><sentence text="Comparison of the Parenteral histamine2-receptor antagonists." /><sentence text="The chemical structure, pharmacokinetic properties, and drug-drug interaction profiles of the parenterally available histamine2 (H2)-receptor antagonists were compared" /><sentence text=" Famotidine is a guanidinothiazole derivative, ranitidine contains an aminomethylfuran ring, and cimetidine has an imidazole ring"><entity charOffset="1-11" id="DDI-PubMed.2573205.s3.e0" text="Famotidine" /><entity charOffset="17-34" id="DDI-PubMed.2573205.s3.e1" text="guanidinothiazole" /><entity charOffset="47-57" id="DDI-PubMed.2573205.s3.e2" text="ranitidine" /><entity charOffset="70-86" id="DDI-PubMed.2573205.s3.e3" text="aminomethylfuran" /><entity charOffset="97-107" id="DDI-PubMed.2573205.s3.e4" text="cimetidine" /><entity charOffset="115-124" id="DDI-PubMed.2573205.s3.e5" text="imidazole" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e0" e2="DDI-PubMed.2573205.s3.e0" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e0" e2="DDI-PubMed.2573205.s3.e1" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e0" e2="DDI-PubMed.2573205.s3.e2" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e0" e2="DDI-PubMed.2573205.s3.e3" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e0" e2="DDI-PubMed.2573205.s3.e4" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e0" e2="DDI-PubMed.2573205.s3.e5" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e1" e2="DDI-PubMed.2573205.s3.e1" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e1" e2="DDI-PubMed.2573205.s3.e2" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e1" e2="DDI-PubMed.2573205.s3.e3" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e1" e2="DDI-PubMed.2573205.s3.e4" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e1" e2="DDI-PubMed.2573205.s3.e5" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e2" e2="DDI-PubMed.2573205.s3.e2" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e2" e2="DDI-PubMed.2573205.s3.e3" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e2" e2="DDI-PubMed.2573205.s3.e4" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e2" e2="DDI-PubMed.2573205.s3.e5" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e3" e2="DDI-PubMed.2573205.s3.e3" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e3" e2="DDI-PubMed.2573205.s3.e4" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e3" e2="DDI-PubMed.2573205.s3.e5" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e4" e2="DDI-PubMed.2573205.s3.e4" /><pair ddi="false" e1="DDI-PubMed.2573205.s3.e4" e2="DDI-PubMed.2573205.s3.e5" /></sentence><sentence text=" Data from the literature indicate that because of its chemical structure famotidine has a much greater potency and affinity for the H2-receptor and a notable lack of drug-drug interactions when compared with ranitidine and cimetidine"><entity charOffset="74-84" id="DDI-PubMed.2573205.s4.e0" text="famotidine" /><entity charOffset="209-219" id="DDI-PubMed.2573205.s4.e1" text="ranitidine" /><entity charOffset="224-234" id="DDI-PubMed.2573205.s4.e2" text="cimetidine" /><pair ddi="false" e1="DDI-PubMed.2573205.s4.e0" e2="DDI-PubMed.2573205.s4.e0" /><pair ddi="false" e1="DDI-PubMed.2573205.s4.e0" e2="DDI-PubMed.2573205.s4.e1" /><pair ddi="false" e1="DDI-PubMed.2573205.s4.e0" e2="DDI-PubMed.2573205.s4.e2" /><pair ddi="false" e1="DDI-PubMed.2573205.s4.e1" e2="DDI-PubMed.2573205.s4.e1" /><pair ddi="false" e1="DDI-PubMed.2573205.s4.e1" e2="DDI-PubMed.2573205.s4.e2" /></sentence><sentence text=" As a result, famotidine should be considered the H2-receptor antagonist of choice for critically ill patients who require gastric-acid suppression and at the same time are being treated with other drugs that depend on the cytochrome P-450 mixed-function oxidase system for their metabolism and/or on renal tubular mechanisms for their excretion"><entity charOffset="14-24" id="DDI-PubMed.2573205.s5.e0" text="famotidine" /></sentence><sentence text="" /></document>